Anthropic’s Long-Term Benefit Trust appoints Vas Narasimhan to Board of Directors
Anthropic’s Long-Term Benefit Trust appoints Vas Narasimhan to Board of Directors
Anthropic 长期利益信托任命 Vas Narasimhan 为董事会成员
Vas Narasimhan has been appointed to Anthropic’s Board of Directors by the Anthropic Long-Term Benefit Trust. He is a physician-scientist and the Chief Executive Officer of Novartis—one of the world’s leading innovative medicines companies—and shares Anthropic’s conviction that healthcare and life sciences are among the areas where AI has the greatest potential to improve the quality of human life.
Vas Narasimhan 已被 Anthropic 长期利益信托（Long-Term Benefit Trust）任命为 Anthropic 董事会成员。他是一位医学科学家，也是全球领先的创新医药公司之一——诺华（Novartis）的首席执行官。他与 Anthropic 持有共同的信念，即医疗保健和生命科学是人工智能最有可能改善人类生活质量的领域。
“Vas brings something rare to our board. He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries,” said Daniela Amodei, Co-founder and President of Anthropic. “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years, and I’m grateful he’s joining us.”
“Vas 为我们的董事会带来了难得的经验。他在监管最严格的行业之一中，监督了 35 多种创新药物的开发和审批，造福了全球患者，”Anthropic 联合创始人兼总裁 Daniela Amodei 表示。“如何安全且大规模地将强大的新技术带给大众，是我们 Anthropic 每天都在思考的问题。Vas 多年来一直在做这件事，我很感激他能加入我们。”
Anthropic is a Public Benefit Corporation and its Board is elected by stockholders and the Long-Term Benefit Trust. The Trust is an independent body whose members have no financial stake in Anthropic, and it exists to keep the company’s governance aligned in a responsible balance between financial success and the company’s public benefit mission of developing AI for the long-term benefit of humanity. With Narasimhan’s appointment, Trust-appointed directors now make up a majority of the Board. Narasimhan joins Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell on the Board of Directors.
Anthropic 是一家公益公司（Public Benefit Corporation），其董事会由股东和长期利益信托共同选举产生。该信托是一个独立机构，其成员在 Anthropic 没有经济利益，其存在旨在确保公司治理在财务成功与“为人类长期利益开发人工智能”这一公益使命之间保持负责任的平衡。随着 Narasimhan 的加入，由信托任命的董事现已在董事会中占据多数席位。Narasimhan 将与 Dario Amodei、Daniela Amodei、Yasmin Razavi、Jay Kreps、Reed Hastings 和 Chris Liddell 一同担任董事会成员。
“The Long-Term Benefit Trust’s role is to appoint directors who will ensure Anthropic responsibly balances its commitment to stockholders and its public benefit mission as the company grows. Vas has spent his career stewarding breakthrough science responsibly —exactly the perspective we are excited to have on the board as we develop consequential technology. We’re excited for what he’ll bring to the table,” said Neil “Buddy” Shah, Chair of Anthropic’s Long-Term Benefit Trust.
“长期利益信托的职责是任命董事，以确保 Anthropic 在公司发展过程中，能够负责任地平衡对股东的承诺与公益使命。Vas 的职业生涯一直致力于负责任地引导突破性科学研究——这正是我们在开发具有深远影响的技术时，非常期待引入董事会的视角。我们对他能带来的贡献感到兴奋，”Anthropic 长期利益信托主席 Neil “Buddy” Shah 说道。
“Working across medicine, innovation, and global health has shown me the transformative potential of technology when deployed responsibly. In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines,” said Narasimhan. “Anthropic is setting the standard for how AI should be developed to benefit humanity, and I’m honored to join the Board and contribute to its mission.”
“在医学、创新和全球健康领域的跨界工作让我看到，当技术被负责任地部署时，它所具备的变革潜力。在医疗保健领域，人工智能正在加速解决一些最艰巨的科学挑战，从加深我们对疾病生物学的理解，到设计更好的药物，”Narasimhan 表示。“Anthropic 正在为如何开发造福人类的人工智能树立标准，我很荣幸能加入董事会并为其使命做出贡献。”
Early in his career, Narasimhan worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America, and he continues to champion access and global health priorities today. He is an elected member of the US National Academy of Medicine and a member of the Council on Foreign Relations. He serves on the University of Chicago board of trustees and the board of fellows at Harvard Medical School. He previously chaired the Pharmaceutical Research and Manufacturers of America, where he remains on the board of directors.
在职业生涯早期，Narasimhan 曾在印度、非洲和南美洲从事艾滋病（HIV/AIDS）、疟疾和结核病的相关项目，至今他仍积极倡导医疗可及性和全球健康优先事项。他是美国国家医学院（US National Academy of Medicine）的当选院士，也是美国外交关系协会（Council on Foreign Relations）的成员。他目前担任芝加哥大学董事会成员以及哈佛医学院研究员委员会成员。他曾担任美国药品研究与制造商协会（PhRMA）主席，目前仍在该协会董事会任职。